Everything below concerns melanocortin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
== Kinetics == The rate at which organostannanes transmetalate with palladium catalysts is shown below. Sp2-hybridized carbon groups attached to tin are the most commonly used coupling partners, and sp3-hybridized carbons require harsher conditions and terminal alkynes may be coupled via a C-H bond through the Sonogashira reaction.
A presentation seen during gameplay reveals that GLaDOS was included in a proposed bid for de-icing fuel lines, incorporated as a fully functional disk-operation system that is arguably alive, unlike Black Mesa's proposal, which inhibits ice, nothing more. After contracting a terminal illness from moon rocks used in portal experiments, Cave decides to attempt to back up his consciousness to a computer. He realises that the technology will not be ready in time to backup his brain due to his imminent demise, and leaves instructions to forcefully backup the consciousness of his assistant Caroline. Upon being uploaded to GLaDOS, Caroline attempts to kill every scientist in the building in under a fraction of a second. After extensive attempts to control her with smaller robots called personality spheres that would act as emotional limits and a sort of artificial "conscience", GLaDOS managed to eventually convince the scientists that she was primarily concerned with science and requested a lethal brain neurotoxin for an experiment about cats. GLaDOS initiated the experiment during the company's first annual bring-your-daughter-to-work day in 1998. Immediately after activation, the facility was flooded with deadly neurotoxin by the AI. Events of the first Half-Life game occur shortly after that, presumably leaving the facility forgotten by the outside world due to apocalyptic happenings. Wolpaw, in describing the ending of Portal 2, affirmed that the Combine invasion, chronologically taking place after Half-Life and before Half-Life 2, had occurred before Portal 2's events.
== Postpartum function == Postpartum CRF1 knockout mice spend less time nursing and less time licking and grooming their offspring than their wildtype counterparts during the first few days postpartum. These pups weighed less as a result. This pattern of maternal behavior indicates that CRF1 may be needed for early postpartum mothers to display typical mothering behaviors. Maternal aggression is attenuated by increases in CRF and urocortin 2, which bind to CRF1.
Actor Jerome Flynn, who starred in Game of Thrones as Bronn, was born in Bromley. Gus Lobban and Jamie Bulled of the band Kero Kero Bonito grew up in Bromley. Deborah Linsley, the victim of one of Britain's most high-profile unsolved murders in 1988, grew up in Bromley. Richard Reid, also known as the "Shoe Bomber", was born and lived in Bromley. He was convicted of the 2001 shoe bomb attempt. In the 20th century, the Parish Church of St Peter and St Paul produced, in quick succession, three Church of England Bishops: Henry David Halsey – Bishop of Carlisle, Philip Goodrich – Bishop of Worcester, David Bartleet – Bishop of Tonbridge. Sculptor Nicholas Cornwell and Maisy James the Big Brother 12 housemate. Sometime before 1881 the engineer and industrialist Richard Porter moved to Beckenham where he remained until his death in 1913. Hanif Kureishi, the writer and filmmaker was born here, and spent a significant part of his youth, here. His first novel The Buddha of Suburbia was loosely based on his life here and the people he lived and met here. Comedian Frankie Boyle claims to be a former resident and has described Bromley as a 'lobotomy made out of bricks'. The comedian Chris Addison currently lives in Bromley, as does tennis player Emma Raducanu. Scottish education secretary Michael Russell MSP was born and spent the early years of his life in Bromley. Member of the Senedd Paul Rock was born in Bromley. Bromley is the home of video game developer Splash Damage.
Sources: en.wikipedia.org
Retrieved 26 September 2021 – via Google Books. Jones, Colin (1994). The Cambridge Illustrated History of France. Cambridge University Press. ISBN 978-0-521-66992-4. Jones, Maldwyn Allen (1992). Boorstin, Daniel J. (ed.). American Immigration. University of Chicago Press. ISBN 978-0-226-40633-6. Kagan, Frederick (2007). The End of the Old Order: Napoleon and Europe, 1801–1805. Hachette Books. ISBN 978-0-306-81645-1. Keeling, Drew (1999). "The Transportation Revolution and Transatlantic Migration". Research in Economic History. 19. Keeling, Drew (1 January 2007). "Transport Capacity Management and Transatlantic Migration, 1900–1914". Research in Economic History. 25. Emerald Group Publishing Limited: 225–283. doi:10.1016/s0363-3268(07)25005-0. ISBN 978-0-7623-1370-9.{{cite journal}}: CS1 maint: periodical has ISBN (link) Keen, Benjamin; Haynes, Keith (2012). A History of Latin America. Cengage Learning. ISBN 978-1-133-70932-9. Kennedy, Paul M. (1989). The Rise and Fall of the Great Powers: Economic Change and Military Conflict from 1500 to 2000. Vintage Books. ISBN 978-0-679-72019-5. Knight, Roger (2013). Britain Against Napoleon: The Organization of Victory, 1793–1815. Penguin UK. ISBN 978-0-14-197702-7. Leggiere, Michael V. (2014). Blücher: Scourge of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4567-9. Malia, Martin Edward (2006). History's Locomotives: Revolutions and the Making of the Modern World. Yale University Press. ISBN 978-0-300-12690-7. McConachy, Bruce (2001). "The Roots of Artillery Doctrine: Napoleonic Artillery Tactics Reconsidered".
Lysyl oxidase the terminal carbon of the side chain of lysyl residue side chain. The enzyme belongsthe category of quinone-containing copper amine oxidases. The reaction requires the cofactor lysyl tyrosylquinone (LTQ). The LTQ cofactor is unique among quinones because it contains an 1,2-benzoquinone substituent. Furthermore, it is neutral charge at physiological pH. The ε-amine is condenses with LTQ to give the Schiff base via reaction with LTQ. The rate-limiting removal of a ε-proton yields an imine. Subsequent hydrolysis of the imine leads to release of the allysine residue. Molecular oxygen and the copper ion are utilized to reoxidize the cofactor, producing hydrogen peroxide as a side product.
Tiegs was elected in 1944 as a Fellow of the Royal Society, aged 47. In 1954 Oscar Tiegs was one of 23 Foundation Fellows of the Australian Academy of Science, and along with the other 22 foundation fellows was a petitioner to Queen Elizabeth II for the Academy's charter. He, Sydney Sunderland, and Thomas MacFarland Cherry, two other petitioners and foundation members were responsible for drafting the by-laws of the newly formed Academy. The Melbourne University's zoological museum, now called the Tiegs Museum, owes much of the quality of its collection to Oscar Tiegs. He spent time and care improving and extending its holdings, based on his belief in the traditional morphological approach to zoology. Oscar Tiegs was a prodigious worker, and, for example, would take on extra lecturing duties during staff absences to not load his other staff, and only in later years did he balance his time more out of work. He was fond of music, in particular Beethoven and Mozart, and critically appreciated pictures. These interests, of music, art, and literature he shared with his wife Ethel. Some felt Oscar Tiegs, while honest, was direct to the point of bluntness, and had a keen sense of humour. He was known for supportive letters sent to friends during World War II, and the gift parcels sent by him and his wife. Oscar Tiegs' geographical isolation, and his own diffidence probably prevented him from maximising his contribution to zoology, although rather than diffidence others describe it as an unassuming disposition.
=== Prosecution in the United States === Following his capture Noriega was transferred to a cell in the Miami federal courthouse, where he was arraigned on the ten charges which the Miami grand jury had returned two years earlier. The trial was delayed until September 1991 over whether Noriega could be tried after his detention as a prisoner of war, the admissibility of evidence and witnesses, and how to pay for Noriega's legal defense. The trial ended in April 1992, when Noriega was convicted on eight of the ten charges of drug trafficking, racketeering, and money laundering. On July 10, 1992, Noriega was sentenced to 40 years in prison. In pre-trial proceedings, the government stated that Noriega had received $322,000 from the U.S. Army and the CIA. Noriega insisted that he had in fact been paid close to $10,000,000, and that he should be allowed to testify about the work he had done for the U.S. government. The district court held that information about the operations in which Noriega had played a part supposedly in return for payment from the U.S. was not relevant to his defense. It ruled that "the tendency of such evidence to confuse the issues before the jury substantially outweighed any probative value it might have had." One of the witnesses in the trial was Carlton, who had previously flown shipments of drugs for Noriega. Information about Noriega's connections to the CIA, including his alleged contact with Bush, were kept out of the trial. After the trial, Noriega appealed this exclusionary ruling by the judge to the Eleventh Circuit Court of Appeals.
=== Active infection === Active infections involve the linear dsDNA genome circularizing by end to end covalent linkages. This process was first reported for the herpes simplex virus. Once circularized, HHV-6 begins to express what are known as "immediate early" genes. These gene products are believed to be transcription activators and may be regulated by the expression of viral micro RNAs. Subsequent expression of "early genes" then occurs and activates, for instance, viral DNA polymerases. Early genes are also involved in the rolling circle replication that follows. HHV-6's replication results in the formation of concatemers, which are long molecules that contain several repeats of a DNA sequence. These long concatemers are then cleaved between the pac-1 and pac-2 regions for packaging of the genome into individual virions.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.